DALLAS and NEW YORK, Aug. 9, 2011 /PRNewswire/ --ACCESS PHARMACEUTICALS, INC.(OTCBB: ACCP),a biopharmaceutical company leveraging its proprietary drug-delivery platforms to develop treatments in areas of oncology, cancer supportive care and diabetes, announced that Community Specialty Pharmacy Network (CSPN), the 10th-largest network of specialty pharmacies in the U.S., has joined its specialty pharmacy network for MuGard, its lead product for oral mucositis. With more than 180 member pharmacies that provide a unique distribution channel for the immediate availability of critical specialty medications, CSPN offers a full range of specialty pharmacy services including mail distribution, clinical services, therapy management and web-based reporting.
“Broadening our specialty pharmacy reach is a key part of our MuGard distribution and market access strategy,” said Anthony Mottola, VP of Managed Care and Market Access, Access Pharmaceuticals, Inc. He continued, “The expansion of our market access strategy which combines various Pharmacy Benefit Managers (PBM’s), like CVS Caremark, large payers like Humana and United Healthcare along with additional networks of specialty pharmacies, such as CSPN gives us the opportunity to provide added patient and provider support services, through our full-service HUB, the MuGard Patient Reimbursement and Support Center (MuGard PRSC).”
Access recently announced the launch of its MuGard Patient Reimbursement and Support Center (MuGard PRSC), a patient referral center that improves patient access to MuGard by enhancing product distribution and facilitating payment for MuGard by insurance carriers. Central to the MuGard PRSC’s initiatives is building a national distribution network of specialty pharmacy providers with in-network or preferred-provider status of most major U.S. health plans.
About MuGard:
MuGard is a novel; ready-to-use mucoadhesive oral wound rinse and coating for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Up to 40% of all patients receiving chemotherapy and radiotherapy develop moderate to severe mucositis, and almost all patients receiving radiotherapy for head and neck cancer and those undergoing stem cell transplantation develop mucositis. Updated clinical practice guidelines for the prevention and treatment of mucositis recommend the use of a preventive oral care regimen as part of routine supportive care along with a therapeutic oral care regimen if mucositis develops. The market for the treatment of oral mucositis is estimated to be in excess of $1 billion world-wide. For more information, please visit www.MuGard.com.
About Access:
Access Pharmaceuticals, Inc. is an emerging biopharmaceutical company that develops and commercializes proprietary products for the treatment and supportive care of cancer patients. Access’ products include MuGard (www.MuGard.com), which has received FDA marketing clearance for the management of patients with mucositis, ProLindac, a second generation DACH Platinum in Phase 2 clinical testing of patients with ovarian cancer, and Thiarabine, a novel nucleoside analog that has demonstrated both pre-clinical and clinical activity in certain cancers; currently in a Phase 1/2a trial in hematological malignancies at M.D. Anderson Cancer Center in Houston, Texas.
The company also has other advanced drug delivery technologies including CobaCyte-mediated targeted delivery and CobOral-oral drug delivery, its proprietary nanopolymer delivery technology
based on the natural vitamin B12 uptake mechanism. For additional information on Access Pharmaceuticals, please visit our website at www.accesspharma.com.
This press release contains certain statements that are forward-looking within the meaning of Section 27a of the Securities Act of 1933, as amended, and that involve risks and uncertainties. These statements include those relating to: our cash burn rate, clinical trial plans and timelines and clinical results for ProLindac, MuGard, Thiarabine and Cobalamin and other product candidates, our ability to achieve clinical and commercial success and our ability to successfully develop marketed products. These statements are subject to numerous risks, including but not limited to Access’ need to obtain additional financing in order to continue the clinical trial and operations and to the risks detailed in Access’ Annual Reports on Form 10-K and other reports filed by Access with the Securities and Exchange Commission.
Contact: Company | Contact: Investor Relations | |
Christine Berni | Donald C. Weinberger/ | |
Director of Investor Relations | Wolfe Axelrod Weinberger Assoc. LLC | |
Access Pharmaceuticals, Inc. | (212) 370-4500 | |
(212) 786-6208 | ||
SOURCE Access Pharmaceuticals, Inc.
